F Lordick
Overview
Explore the profile of F Lordick including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
127
Citations
3513
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dienstmann R, Ruiz-Garcia E, Alsina M, Ruiz-Pace F, Groen-van Schooten T, Martinez-Ciarpaglini C, et al.
ESMO Open
. 2025 Mar;
10(3):104482.
PMID: 40036904
Background: Gastric cancer (GC) is recognized for intrinsic heterogeneity, although it is similarly approached in Europe and Latin America (LATAM). The LEGACY project aimed to deepen GC molecular understanding through...
2.
Lordick F, Mauer M, Stocker G, Cella C, Ben-Aharon I, Piessen G, et al.
Ann Oncol
. 2024 Nov;
36(2):197-207.
PMID: 39542422
Background: Patients with gastro-oesophageal adenocarcinoma with tumour-positive lymph nodes (ypN+) or positive surgical margins (R1) following neoadjuvant chemotherapy and resection are at high risk of recurrence. Adjuvant nivolumab is effective...
3.
Lordick F, Van Cutsem E, Shitara K, Xu R, Ajani J, Shah M, et al.
ESMO Open
. 2024 Aug;
9(8):103663.
PMID: 39146670
Background: First-line zolbetuximab plus chemotherapy (SPOTLIGHT, mFOLFOX6; GLOW, CAPOX) significantly improved progression-free survival (PFS) and overall survival (OS) versus placebo plus chemotherapy in patients with human epidermal growth factor receptor...
4.
Goerling U, Ernst J, Esser P, Haering C, Hermann M, Hornemann B, et al.
ESMO Open
. 2024 Aug;
9(8):103655.
PMID: 39088984
Background: The purpose of this study was to provide the 4-week prevalence estimates of mental disorders in newly diagnosed cancer patients in relation to socioeconomic status (SES). Patients And Methods:...
5.
Baretton G, Lordick F, Gaiser T, Hofheinz R, Horst D, Lorenzen S, et al.
Pathologie (Heidelb)
. 2024 Jan;
45(1):51-58.
PMID: 38170268
As a result of the high approval dynamics and the growing number of immuno-oncological therapy concepts, the complexity of therapy decisions and control in the area of carcinomas of the...
6.
Comoli P, Pentheroudakis G, Ruggeri A, Koehl U, Lordick F, Mooyaart J, et al.
Ann Oncol
. 2023 Dec;
35(4):404-406.
PMID: 38145867
No abstract available.
7.
Illert A, Stenzinger A, Bitzer M, Horak P, Gaidzik V, Moller Y, et al.
Nat Med
. 2023 Jun;
29(6):1298-1301.
PMID: 37280276
No abstract available.
8.
Stocker G, Lorenzen S, Ettrich T, Herz A, Longo F, Kiani A, et al.
ESMO Open
. 2023 Jun;
8(3):101572.
PMID: 37270871
Purpose: Platinum-fluoropyrimidine combinations are standard of care for treatment of metastatic esophagogastric adenocarcinoma. The optimal duration of first-line chemotherapy is unknown, however, and maintenance strategies have not yet been established....
9.
Ducreux M, Abou-Alfa G, Bekaii-Saab T, Berlin J, Cervantes A, de Baere T, et al.
ESMO Open
. 2023 Jun;
8(3):101567.
PMID: 37263081
This article summarises expert discussion on the management of patients with hepatocellular carcinoma (HCC), which took place during the 24th World Gastrointestinal Cancer Congress (WGICC) in Barcelona, July 2022. A...
10.
Zarkavelis G, Amylidi A, Verbaanderd C, Cherny N, Metaxas Y, de Vries E, et al.
ESMO Open
. 2023 Mar;
8(1):100604.
PMID: 36870739
Introduction: Off-label use of medicines is generally discouraged. However, several off-patent, low-cost cancer medicines remain off-label for indications in which they are commonly used in daily practice, supported by high-level...